CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03600649
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:27.815358+00:00
Published At: 2023-11-21T00:00:00+00:00
Record Updated At: 2023-11-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ewing Sarcoma", "Myxoid Liposarcoma", "Sarcoma,Soft Tissue", "Desmoplastic Small Round Cell Tumor", "Extraskeletal Myxoid Chondrosarcoma", "Angiomatoid Fibrous Histiocytoma", "Clear Cell Sarcoma", "Primary Pulmonary Myxoid Sarcoma", "Myoepithelial Tumor", "Sclerosing Epithelioid Fibrosarcoma", "Fibromyxoid Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-11-21"
protocolSection.identificationModule.nctId: "NCT03600649"
protocolSection.identificationModule.officialTitle: "Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.